Merus

• Capital Increase of 7,840,909 common shares at a price of USD 22.00, generating gross proceeds of USD 173 million for Merus at a discount of 3.9% to the last closing price
• The transaction was launched on the back of Q2 2023 financial results that included a business update that mentioned petosemab was granted FDA Fast Track Designation for head and neck cancer and the plan to start a Phase III trial in mid-2024. Furthermore, the company announced zenocutuzumab was granted two FDA Breakthrough Therapy Designations in both NRG1+ non-small cell lung cancer (NSCLC) and NRG1+ pancreatic cancer
• Merus intends to use the proceeds to advance the clinical development of its product candidates, its preclinical research and development efforts, and general corporate purposes
• Van Lanschot Kempen acted as the only European Bank in a US banking syndicate and is proud to have assisted Merus as a repeat client in raising capital for the fourth time since 2019

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Manager in the USD 1.3 billion Capital Increase by argenx
• Joint Bookrunner in the SEK 500m Capital Increase by Vicore Pharma
• Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors
• Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics 
• Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
• Lead Manager in the USD 250 million US Public Offering by CureVac
• Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
• Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
• Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
• Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
• Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
• Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank 
• Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
• Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
• Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
• Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
• Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
• Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50 million Fully Guaranteed Rights Issue by Abliva
• Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma